Logo image
Microtubule Inhibitors and Cardiotoxicity
Journal article   Open access   Peer reviewed

Microtubule Inhibitors and Cardiotoxicity

Amogh M Joshi, George S Prousi, Christopher Bianco, Midhun Malla, Avirup Guha, Mahek Shah, Sherry-Ann Brown and Brijesh Patel
Current oncology reports, v 23(3), 30
Mar 2021
PMID: 33582937
url
https://www.ncbi.nlm.nih.gov/pmc/articles/8414965View
Open

Abstract

Cardiotoxicity - etiology Heart Diseases - chemically induced Humans Neoplasms - drug therapy Tubulin Modulators - adverse effects Tubulin Modulators - therapeutic use
Cancer and heart disease are the leading causes of mortality in the USA. Advances in cancer therapies, namely, the development and use of chemotherapeutic agents alone or in combination, are becoming increasingly prevalent. Many chemotherapeutic agents have been associated with adverse cardiovascular manifestations. The mechanisms of these sequelae remain incompletely understood. In particular, microtubule inhibitor (MTI) agents have been related to the development of heart failure, myocardial ischemia, and conduction abnormalities. At present, there are no guidelines for patients undergoing MTI therapy as it pertains to both preventative and mitigatory strategies for cardiovascular complications. We conducted a literature review focusing on content related to the use of MTIs and their effect on the cardiovascular system. MTIs have been associated with various forms of cardiotoxicity, and fatal cardiotoxicities are rare. The most well-described cardiotoxicities are brady- and tachyarrhythmias. The co-administration of anthracycline-based agents with MTIs can increase the risk of cardiotoxicity.

Metrics

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Oncology
Logo image